data, NCI-sponsored clinical trials to examine the potential of arsenic trioxide for the treatment of solid tumours are under way or in the final planning stages.

4. Summary of the Invention

The present invention relates to a pharmaceutical composition intended for the treatment of urogenital diseases and bone metastasis and to a method of treating such diseases.

In one aspect, provided herein is use of sodium meta arsenite in the manufacture of a medicament for the treatment of multiple myeloma in human.

Accordingly, the present invention provides a pharmaceutical composition intended for the treatment of urogenital diseases and bone metastasis in a human, wherein said pharmaceutical composition contains an effective amount of arsenous acid alkaline or earth alkaline metal salt and/or a pharmaceutically acceptable adjuvant.

According to the present invention, said alkaline arsenous acid metal salt is sodium meta-arsenite (AsO_2Na) or potassium meta-arsenite (AsO_2K).

The effective amount of arsenous acid alkaline or earth alkaline metal salt is 0.0001-1500 mg/kg, preferably 1-1000 mg/kg, more preferably 1-150 mg/kg, and most preferably 50-100 mg/kg of body weight/day.

Said pharmaceutical composition preferably occurs in an oral administration form, wherein said oral administration form is e.g. a tablet, capsule, powder and/or solution with